(864) 370-3297 info@glytecsystems.com
Glytec_Logo_RGB
  • About
    • About Glytec
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Newsroom
    • Careers
    • Contact Us
  • Solutions
    • eGlycemic Management System
    • Implementation & Support
    • Quality Initiatives
    • Sliding Scale to Basal Bolus Transition
  • Resources
    • All Resources
    • Hospital Pharmacy Resources
    • CMS's Hospital Harm Measures on Severe Hypo and Hyperglycemia
    • Nurse Resources
    • Evidence
  • Case Studies
  • Blog
  • Request a Demo

Resources

Glytec offers a wide array of resources describing how our solutions improve clinical and financial outcomes through standardization of care and best practices in diabetes therapy and glycemic management.

Filter by Type
Video Whitepaper Case Study Guide eBook
  • There are no suggestions because the search field is empty.
Video,

eGlycemic Management System Video Overview

Whitepaper,

GlucoMetrics: Glytec’s Analytics and Reporting Platform

Case Study

AdventHealth Waterman | Implementing eGMS® Case Study | Glytec

Podcast

Becker's Podcast - Preparing for CMS Hospital Harm Measures

Video

Mastering the Meal Triad: Best Practices & Implementation Strategies

Video

Spotlight on Perioperative Glycemic Management: A Technology-Driven Approach

Video

Inpatient Glycemic Management Best Practices: Strategies and Applications

Video

Reducing Hospital Harm: The Pharmacists' Perspective

Video

Success Stories: Continuous Improvement

Video

CMS Measures: Preparing Your Health System

Video

Continuous Glucose Monitoring in the Management of Hospitalized Patients with Hyperglycemia and Diabetes

Case Study,

Sentara Virginia Beach General

Case Study,

Novant Health Achieves Quality Improvement at Scale with Cross-Functional Collaboration

eGlycemic-Management-System
Video

eGlycemic Management System Video Overview

Case Study

Grady Health

Prev 1 2 3 4 5 Next

Subscribe to our blog

Glytec_Logo_white-transp

Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes.

  • Terms of Use
  • Legal Disclaimer
  • Privacy Policy
  • Contraindications, Warnings and Precautions
© 2023 Glytec, LLC on behalf of Aseko, Inc.

The eGlycemic Management System® is a modularized solution for glycemic management across the care continuum that includes Glucommander™. Glucommander™ is a prescription-only software medical device for glycemic management intended to evaluate current as well as cumulative patient blood glucose values coupled with patient information including age, weight and height, and, based on the aggregate of these measurement parameters, whether one or many, recommend an IV dosage of insulin, glucose or saline or a subcutaneous basal and bolus insulin dosing recommendation to adjust and maintain the blood glucose level towards a configurable physician- determined target range. Glucommander™ is indicated for use in adult and pediatric (ages 2-17 years) patients. The measurements and calculations generated are intended to be used by qualified and trained medical personnel in evaluating patient conditions in conjunction with clinical history, symptoms, and other diagnostic measurements, as well as the medical professional’s clinical judgement. No medical decision should be based solely on the recommended guidance provided by this software program.

Glucommander™ is only available for use in the United States.

This site is only intended for use in the United States.

Aseko is a registered trademark of Aseko, Inc.